NMDA receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 72 hours
DelveInsight’s, “NMDA Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in NMDA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
NMDA Receptor Antagonists: Overview
The NMDA receptor is an ionotropic receptor that allows for the transfer of electrical signals between neurons in the brain and in the spinal column. N-methyl-D-aspartate receptor is a ligand of glutamate, which is the primary excitatory neurotransmitter in the human brain. The activation of NMDA receptors has been associated with hyperalgesia, neuropathic pain, and reduced functionality of opioid receptors. Molecules that block the NMDA receptor are called NMDA-receptor antagonists. N-methyl-D-aspartate receptors are also expressed across a wide spectrum of non-neuronal cells, including central and peripheral glial cells, endothelium, bone, kidney, pancreas, and others. NMDA-receptor antagonists can be used in the management of chronic pain and Alzheimer's disease. Commercially available NMDA-receptor antagonists include ketamine, dextromethorphan, memantine, and amantadine. The opioids methadone, dextropropoxyphene, and ketobemidone are also antagonists at the NMDA receptor.
Report Highlights
This segment of the NMDA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NMDA Receptor Antagonists Emerging Drugs
Further product details are provided in the report……..
NMDA Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different NMDA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
NMDA Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NMDA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NMDA Receptor Antagonists drugs.
NMDA Receptor Antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “NMDA Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in NMDA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
NMDA Receptor Antagonists: Overview
The NMDA receptor is an ionotropic receptor that allows for the transfer of electrical signals between neurons in the brain and in the spinal column. N-methyl-D-aspartate receptor is a ligand of glutamate, which is the primary excitatory neurotransmitter in the human brain. The activation of NMDA receptors has been associated with hyperalgesia, neuropathic pain, and reduced functionality of opioid receptors. Molecules that block the NMDA receptor are called NMDA-receptor antagonists. N-methyl-D-aspartate receptors are also expressed across a wide spectrum of non-neuronal cells, including central and peripheral glial cells, endothelium, bone, kidney, pancreas, and others. NMDA-receptor antagonists can be used in the management of chronic pain and Alzheimer's disease. Commercially available NMDA-receptor antagonists include ketamine, dextromethorphan, memantine, and amantadine. The opioids methadone, dextropropoxyphene, and ketobemidone are also antagonists at the NMDA receptor.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence NMDA Receptor Antagonists R&D. The therapies under development are focused on novel approaches for NMDA Receptor Antagonists.
This segment of the NMDA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NMDA Receptor Antagonists Emerging Drugs
- NP-120 (Ifenprodil): Algernon Pharmaceuticals
- REL 1017: Relmada Therapeutics
Further product details are provided in the report……..
NMDA Receptor Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different NMDA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on NMDA Receptor Antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
NMDA Receptor Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NMDA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NMDA Receptor Antagonists drugs.
NMDA Receptor Antagonists Report Insights
- NMDA Receptor Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing NMDA Receptor Antagonists drugs?
- How many NMDA Receptor Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for NMDA Receptor Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NMDA Receptor Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for NMDA Receptor Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Algernon Pharmaceuticals
- Relmada Therapeutics
- UCB
- Avanir Pharmaceuticals
- Axsome Therapeutics
- Seelos Therapeutics
- PharmaTher
- Cessatech
- ATAI Life Sciences
- Small Pharma
- Bexson Biomedical
- DemeRx
- NP-120 (Ifenprodil)
- REL 1017
- Lacosamide
- Deudextromethorphan
- AXS-05
- SLS-002
- Ketamine microneedle patch
- CT-001
- PCN-101
- SPL-801-B
- BB-106
- Ibogaine
Introduction
Executive Summary
NMDA Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
NMDA Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NMDA Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NMDA Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
REL 1017: Relmada Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
NP-120 (Ifenprodil): Algernon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Ketamine microneedle patch: PharmaTher
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SPL-801-B: Small Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NMDA Receptor Antagonists Key Companies
NMDA Receptor Antagonists Key Products
NMDA Receptor Antagonists- Unmet Needs
NMDA Receptor Antagonists- Market Drivers and Barriers
NMDA Receptor Antagonists- Future Perspectives and Conclusion
NMDA Receptor Antagonists Analyst Views
NMDA Receptor Antagonists Key Companies
Appendix
Executive Summary
NMDA Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
NMDA Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NMDA Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NMDA Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
REL 1017: Relmada Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
NP-120 (Ifenprodil): Algernon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Ketamine microneedle patch: PharmaTher
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SPL-801-B: Small Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NMDA Receptor Antagonists Key Companies
NMDA Receptor Antagonists Key Products
NMDA Receptor Antagonists- Unmet Needs
NMDA Receptor Antagonists- Market Drivers and Barriers
NMDA Receptor Antagonists- Future Perspectives and Conclusion
NMDA Receptor Antagonists Analyst Views
NMDA Receptor Antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for NMDA Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for NMDA Receptor Antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for NMDA Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for NMDA Receptor Antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
